Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

Also called NCT07770282

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07770282
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07770282. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2030-07-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Condition
Schizophrenia Disorder
Condition
Antipsychotic-induced Weight Gain
Condition
Cardiovascular Risk
Intervention (Drug)
Semaglutide + TAU
Intervention (Drug)
Placebo + TAU
Lead sponsor
All India Institute of Medical Sciences, Bhubaneswar (class: other)
Collaborator
Indian Council of Medical Research (class: other government)

Record details

Record id
cardio:ct-nct07770282
Content hash
da2404f718b97ed125fc7e6a54e9cf85abcc06624f0c3918e4c307833f23f8b9